CollPlant Biotechnologies (CLGN) to Release Quarterly Earnings on Thursday

CollPlant Biotechnologies (NASDAQ:CLGN - Get Free Report) will post its quarterly earnings results before the market opens on Thursday, April 4th. Analysts expect CollPlant Biotechnologies to post earnings of ($0.07) per share for the quarter. Parties interested in participating in the company's conference call can do so using this link.

CollPlant Biotechnologies Trading Up 3.1 %

NASDAQ:CLGN traded up $0.16 during trading hours on Thursday, reaching $5.39. The company had a trading volume of 2,648 shares, compared to its average volume of 9,068. CollPlant Biotechnologies has a 1-year low of $4.22 and a 1-year high of $8.90. The business's 50 day moving average price is $5.32 and its 200-day moving average price is $5.54.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a "buy" rating and set a $11.00 price target on shares of CollPlant Biotechnologies in a research report on Thursday, November 30th.

Hedge Funds Weigh In On CollPlant Biotechnologies

A number of hedge funds have recently modified their holdings of the business. LPL Financial LLC acquired a new position in CollPlant Biotechnologies during the 2nd quarter worth about $361,000. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in CollPlant Biotechnologies in the 2nd quarter valued at about $189,000. Jane Street Group LLC acquired a new stake in CollPlant Biotechnologies in the 3rd quarter valued at about $90,000. UBS Group AG raised its position in CollPlant Biotechnologies by 119.1% in the 2nd quarter. UBS Group AG now owns 7,514 shares of the company's stock valued at $60,000 after purchasing an additional 4,085 shares in the last quarter. Finally, Bank of America Corp DE raised its position in CollPlant Biotechnologies by 53.9% in the 1st quarter. Bank of America Corp DE now owns 7,389 shares of the company's stock valued at $52,000 after purchasing an additional 2,589 shares in the last quarter. 21.69% of the stock is currently owned by hedge funds and other institutional investors.

CollPlant Biotechnologies Company Profile

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, and Europe. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology.